Current stock page

Catalysts

VSTM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

VSTMVerastem, Inc.

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$8.18−$0.26 (−3.08%)

Latest quote

  • Momentum
    89
  • Value
    53
  • Quality
    42
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Mar 3, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 60/100

Momentum 89/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 2.66%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 89/100AIQ Edge 6/10 Above Peers
Beat rate
50%
4 of 8 reported periods
Average surprise
-25.7%
Across covered historical reports
Latest result
-56.5%
Nov 5, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 5, 2026—-$0.47-$0.74-56.5%$26.57M$24.01M
Aug 6, 2026—-$0.43-$0.35+18.7%$22.88M$40.08M
May 7, 2026—-$0.46-$0.37+19.6%$21.43M$18.67M
Mar 4, 2026—-$0.49-$0.39+20.4%$16.9M$17.54M
Nov 4, 2025—-$0.51-$1.35-164.7%$16.53M$11.24M
Aug 7, 2025—-$0.85-$0.39+54.1%$5.7M$2.14M
May 13, 2025—-$0.72-$0.96-33.3%$100K—
Mar 20, 2025—-$0.81-$1.33-64.2%$150K$9.98M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
10
Buy
12-month analyst target
$18.50
+126.16% versus current price
Based on 10 analyst observations. Targets are estimates, not predictions.
Low target
$13.00
+58.92% vs latest price
Average target
$18.50
+126.16% vs latest price
High target
$22.00
+168.95% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateMar 3, 2027

Next known earnings or reporting date.

EPS estimate-$0.53

Current analyst expectation for the upcoming report.

Revenue estimate$29.08M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score89

Where event reaction would show up first.

AIQ score60/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
10
Average target
$18.50
Target upside
126.16%
Target range
$13.00 - $22.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
1
Negative
1
gurufocus.com · Oct 19, 2026

VSTM Reiterated by BTIG -- Price Target Maintained at $24.00

On October 16, 2026, Verastem Inc (VSTM) received a 'Buy' rating from BTIG, with the price target remaining unchanged at $24.00. This rating comes amidst a seri

gurufocus.com · Oct 16, 2026

VSTM Maintained by Mizuho -- Price Target Raised to $14.00

On October 16, 2026, Mizuho analyst Graig Suvannavejh maintained the rating for Verastem (VSTM) while raising the price target to $14.00, up from the previous t

gurufocus.com · Oct 15, 2026

VSTM Maintained by Jefferies -- Price Target Raised to $13.00

Verastem Inc (VSTM) Analyst Rating Update - October 2023 On October 10, 2023, Jefferies maintained a "Buy" rating on Verastem (VSTM). The price target has be

gurufocus.com · Oct 15, 2026

VSTM Maintained by RBC Capital -- Price Target Raised to $19

Verastem Inc (VSTM) Analyst Rating Update On October 15, 2026, RBC Capital maintained an "Outperform" rating for Verastem (VSTM). The price target was raised

seekingalpha.com · Oct 15, 2026

Verastem: A Real Pancreatic Cancer Drug, Arriving Second (NASDAQ:VSTM)

Verastem (VSTM) stock outlook: Hold rating as VS-7375 KRAS G12D data shows promise, but dilution, competition, and cash burn persist—read now.

Open full news and sentiment

VSTM Catalysts FAQ

What are the next catalysts for VSTM stock?

VSTM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move VSTM stock?

Upcoming events that could move VSTM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could VSTM's next earnings report affect the stock?

VSTM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive VSTM stock higher?

VSTM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt VSTM stock?

VSTM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.